Literature DB >> 25477334

MDM2-p53 pathway in hepatocellular carcinoma.

Xuan Meng1, Derek A Franklin2, Jiahong Dong3, Yanping Zhang4.   

Abstract

Abnormalities in the TP53 gene and overexpression of MDM2, a transcriptional target and negative regulator of p53, are commonly observed in cancers. The MDM2-p53 feedback loop plays an important role in tumor progression and thus, increased understanding of the pathway has the potential to improve clinical outcomes for cancer patients. Hepatocellular carcinoma (HCC) has emerged as one of the most commonly diagnosed forms of human cancer; yet, the current treatment for HCC is less effective than those used against other cancers. We review the current studies of the MDM2-p53 pathway in cancer with a focus on HCC and specifically discuss the impact of p53 mutations along with other alterations of the MDM2-p53 feedback loop in HCC. We also discuss the potential diagnostic and prognostic applications of p53 and MDM2 in malignant tumors as well as therapeutic avenues that are being developed to target the MDM2-p53 pathway. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25477334      PMCID: PMC4504428          DOI: 10.1158/0008-5472.CAN-14-1446

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  64 in total

1.  Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo.

Authors:  Holly K Koblish; Shuyuan Zhao; Carol F Franks; Robert R Donatelli; Rose M Tominovich; Louis V LaFrance; Kristi A Leonard; Joan M Gushue; Daniel J Parks; Raul R Calvo; Karen L Milkiewicz; Juan José Marugán; Pierre Raboisson; Maxwell D Cummings; Bruce L Grasberger; Dana L Johnson; Tianbao Lu; Christopher J Molloy; Anna C Maroney
Journal:  Mol Cancer Ther       Date:  2006-01       Impact factor: 6.261

2.  Novel amino-modified silica nanoparticles as efficient vector for hepatocellular carcinoma gene therapy.

Authors:  Xuxian Xiao; Qiongqiong He; Kelong Huang
Journal:  Med Oncol       Date:  2009-12-01       Impact factor: 3.064

3.  MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C.

Authors:  Narayan Dharel; Naoya Kato; Ryosuke Muroyama; Masaru Moriyama; Run-Xuan Shao; Takao Kawabe; Masao Omata
Journal:  Clin Cancer Res       Date:  2006-08-15       Impact factor: 12.531

Review 4.  p53 gene in treatment of hepatic carcinoma: status quo.

Authors:  Yong-Song Guan; Zi La; Lin Yang; Qing He; Ping Li
Journal:  World J Gastroenterol       Date:  2007-02-21       Impact factor: 5.742

5.  Targeting p53 for Novel Anticancer Therapy.

Authors:  Zhen Wang; Yi Sun
Journal:  Transl Oncol       Date:  2010-02       Impact factor: 4.243

6.  New p53 target, phosphatase of regenerating liver 1 (PRL-1) downregulates p53.

Authors:  S-H Min; D M Kim; Y-S Heo; Y-I Kim; H M Kim; J Kim; Y-M Han; I-C Kim; O-J Yoo
Journal:  Oncogene       Date:  2008-11-10       Impact factor: 9.867

7.  Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition.

Authors:  Mu-Shui Dai; Shelya X Zeng; Yetao Jin; Xiao-Xin Sun; Larry David; Hua Lu
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

8.  Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis.

Authors:  Joel R Pekow; Atul K Bhan; Hui Zheng; Raymond T Chung
Journal:  Cancer       Date:  2007-06-15       Impact factor: 6.860

9.  p53 regulates a mitotic transcription program and determines ploidy in normal mouse liver.

Authors:  Svitlana Kurinna; Sabrina A Stratton; Zeynep Coban; Jill M Schumacher; Markus Grompe; Andrew W Duncan; Michelle Craig Barton
Journal:  Hepatology       Date:  2013-02-15       Impact factor: 17.425

Review 10.  Activation and activities of the p53 tumour suppressor protein.

Authors:  E Bálint E; K H Vousden
Journal:  Br J Cancer       Date:  2001-12-14       Impact factor: 7.640

View more
  89 in total

1.  Association of RNF43 with cell cycle proteins involved in p53 pathway.

Authors:  Haiyang Xie; Chunyang Xing; Guoqiang Cao; Bajin Wei; Xiao Xu; Penghong Song; Leiming Chen; Hai Chen; Shengyong Yin; Lin Zhou; Shusen Zheng
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

2.  Elevated expression of cellular SYNE1, MMP10, and GTPase1 and their regulatory role in hepatocellular carcinoma progression.

Authors:  Laila H Faraj Shaglouf; Maryam Ranjpour; Saima Wajid; Swatantra Kumar Jain
Journal:  Protoplasma       Date:  2019-08-19       Impact factor: 3.356

3.  High-resolution protein-protein interaction mapping using all-versus-all sequencing (AVA-Seq).

Authors:  Simeon S Andrews; Stephanie Schaefer-Ramadan; Nayra M Al-Thani; Ikhlak Ahmed; Yasmin A Mohamoud; Joel A Malek
Journal:  J Biol Chem       Date:  2019-06-10       Impact factor: 5.157

Review 4.  The role of MDM2-p53 axis dysfunction in the hepatocellular carcinoma transformation.

Authors:  Hui Cao; Xiaosong Chen; Zhijun Wang; Lei Wang; Qiang Xia; Wei Zhang
Journal:  Cell Death Discov       Date:  2020-06-19

5.  Up-regulation of small nucleolar RNA 78 is correlated with aggressive phenotype and poor prognosis of hepatocellular carcinoma.

Authors:  Pei Ma; Haitao Wang; Lu Han; Wei Jing; Xin Zhou; Zhisu Liu
Journal:  Tumour Biol       Date:  2016-10-21

6.  Overexpression of Protein Phosphatase 1γ (PP1γ) Is Associated with Enhanced Cell Proliferation and Poor Prognosis in Hepatocellular Carcinoma.

Authors:  Chunsun Li; Miaomiao Wu; Guijuan Zong; Chunhua Wan; Qingqing Liu; Huiling Zhou; Lu Hua; Yuyan Chen; Xudong Chen; Cuihua Lu
Journal:  Dig Dis Sci       Date:  2016-12-05       Impact factor: 3.199

Review 7.  Apoptosis in liver carcinogenesis and chemotherapy.

Authors:  Joaquim Moreno-Càceres; Isabel Fabregat
Journal:  Hepat Oncol       Date:  2015-11-11

8.  MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53.

Authors:  Wei Wang; Jian-Wen Cheng; Jiang-Jiang Qin; Bo Hu; Xin Li; Bhavitavya Nijampatnam; Sadanandan E Velu; Jia Fan; Xin-Rong Yang; Ruiwen Zhang
Journal:  Cancer Lett       Date:  2019-06-07       Impact factor: 8.679

Review 9.  Signaling Pathways as Potential Therapeutic Targets in Hepatocarcinogenesis.

Authors:  Yeliz Yılmaz; Ayşim Güneş; Hande Topel; Neşe Atabey
Journal:  J Gastrointest Cancer       Date:  2017-09

Review 10.  The FHL2 regulation in the transcriptional circuitry of human cancers.

Authors:  Cyanne Ye Cao; Simon Wing-Fai Mok; Vincent Wing-Sang Cheng; Stephen Kwok-Wing Tsui
Journal:  Gene       Date:  2015-07-26       Impact factor: 3.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.